Docetaxel for Breast Cancer Treatment-Side Effects on Ocular Surface, a Systematic Review

Docetaxel is a very effective chemotherapeutic agent for the treatment of metastatic or locally advanced breast cancer. Epiphora (hyperlacrimation) has been shown to be most common eye condition in patients receiving docetaxel-based chemotherapy. This symptom does not decrease visual acuity, but decreases quality life. Daily activities (reading, working on computer, watching TV, and so on) are affected, with complaining about an alteration daily life appearance this symptom. The mechanism by which epiphora occurs considered canalicular stenosis, trials subject failed reach statistical significance. objective scoping review determine whether there regimen-dependent relationship between docetaxel administration presence women inclusion criteria were met 10 trials, from one was excluded owing data selection biases. Accordingly, nine studies evaluated quantitatively qualitatively present review. We included subjects as single combination other chemotherapy compounds. occurrence among treated docetaxel, regardless therapeutic regimen used, statistically significant (p = 0.005). proportion after weekly (54 out 131 subjects, 41.22%) different compared that those who received at three week intervals (112 325 34.15%), difference two 0.732). study demonstrates more frequently than taking three-weekly regimen, significant. Ophthalmologic assessment all starting recommended. causal stenosis fully elucidated long ocular do have lacrimal system. Further well-designed required bring new insights into mechanisms pathogenesis docetaxel.